American Century Companies Inc. Purchases 83,660 Shares of Progyny, Inc. $PGNY

American Century Companies Inc. raised its position in Progyny, Inc. (NASDAQ:PGNY) by 445.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 102,443 shares of the company’s stock after acquiring an additional 83,660 shares during the period. American Century Companies Inc. owned about 0.12% of Progyny worth $2,289,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of Progyny by 233.9% during the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company’s stock worth $120,000 after purchasing an additional 3,768 shares in the last quarter. State of Wyoming raised its stake in Progyny by 98.2% in the 4th quarter. State of Wyoming now owns 12,376 shares of the company’s stock valued at $213,000 after acquiring an additional 6,132 shares during the period. Sei Investments Co. bought a new stake in Progyny in the 1st quarter valued at $228,000. XTX Topco Ltd bought a new stake in Progyny in the 1st quarter valued at $241,000. Finally, Corton Capital Inc. bought a new stake in Progyny in the 4th quarter valued at $264,000. Institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PGNY shares. Leerink Partners upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price target on the stock in a research note on Tuesday, July 8th. Canaccord Genuity Group increased their price target on Progyny from $21.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 20th. Raymond James Financial set a $28.00 price target on Progyny in a research note on Friday, August 8th. Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.30.

Insider Buying and Selling at Progyny

In other news, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director directly owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. This represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Cheryl Scott sold 2,675 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the sale, the director directly owned 14,112 shares in the company, valued at approximately $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.40% of the company’s stock.

Progyny Price Performance

Shares of NASDAQ PGNY opened at $23.67 on Monday. The stock’s fifty day moving average price is $22.73 and its two-hundred day moving average price is $22.20. Progyny, Inc. has a one year low of $13.39 and a one year high of $26.76. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 40.12, a P/E/G ratio of 1.94 and a beta of 1.33.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same period in the prior year, the company earned $0.17 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.